ERLOCIP

DESCRIPTION

                          Erlocip 150mg tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlocip 150mg tablet is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor. 

Erlocip 150mg

INDICATION AND USAGE

                          Erlocip 150mg tablets are prescription medicine, used only by the patients who have valid prescription

Erlocip 150mg tablet is primarily indicated for; Non small cell lung cancer: Erlocip 150mg tablet is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlocip 150mg is involved in the treatment of non-small cell lung cancer patients whose cancer cells containing epidermal growth factor receptors on their surface. Erlocip 150mg tablet is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlocip 150mg tablet is used in combination with gemcitabine. In this condition Erlocip is involved as first line treatment.

WARNING

                         Some of the adverse effects occur while treating with Erlocip tablets; Interstitial lung disease Renal impairment Hepatic toxicity with liver failure Gastrointestinal perforation Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia Hemorrhage Ocular disorders Embryo fetal toxicity

ERLOCIP PHARMACOLOGY

                       Erlocip 150mg tablet has pharmacological effects like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal growth factor receptor. This EGFR is occurs on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.

ERLOCIP ADME PROPERTY

ABSORPTION

                           The peak plasma concentration time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its bioavailability to 100%. The Erlotinib solubility is depends upon pH level. The reduction in solubility causes elevation of the pH levels. Smoking should be avoided during the treatment with Erlocip , causes decreasing the exposure of Erlotinib.

DISTRIBUTION

                          Volume of distribution of Erlotinib is 232L Human protein binding to Erlotinib is occurs as 93%.

METABOLISM

                        The metabolism of Erlotinib is occurs by CYP3A4

ELIMINATION

                        The route of elimination of Erlotinib metabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.

PRODUCT DETAILS

Brand : Erlocip

Ingredients : Erlotinib

Strength : 150mg

Manufactured : Cipla

Package : 30 Tablets

DOSAGE ADMINISTRATION

DOSAGE MANAGEMENT

                                      In NSCLC: The recommended dosage is 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlocip 150mg tablet is 100mg should be taken as a single dose by administering on an empty stomach by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Interstitial lung disease, pulmonary failure: Discontinue the Erlocip therapy In severe hepatic failure: Stop the therapy permanently

In renal impairment: Discontinue the Erlocip 150mg therapy permanently In gastrointestinal perforation and severe diarrhea: Stop the therapy In severe Bullous and exfoliative skin disorders: Discontinue the therapy and provide supportive measures In corneal perforation, therapy should be discontinuing permanently. Avoid concomitant use of Erlocip with CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc.

SIDE EFFECT

SOME SERIOUS ADVERSE EFFECT

                                 Renal failure Liver toxicity with failure Gastrointestinal perforations Ocular disorders Hemorrhage Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia

SOME COMMON SIDE EFFECTS

                            Rash Diarrhea Cough Dyspnea Dry skin Back pain Conjunctivitis Mucosal inflammation Pruritus Paronychia Chest pain, arthralgia Musculoskeletal pain Myopathy like rhabdomyolysis while combining with liqid lowering drugs

CYP3A4 INHIBITORS:

                           Concomitant use of Erlocip 150mg with CYP3A4 inhibitors like (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketaconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) causes increasing the exposure of Erlotinib. This result as increase in risk of adverse effects related to Erlocip . 

IN CYP3A4 INDUCERS:

                          In combination of Erlocip with CYP3A4 inducers like anti-convulsants, rifampin, rifampicin, st Johns wort etc causes decreasing the exposure of Erlotinib. Thus results as decrease in therapeutic effect of Erlocip 150mg tablet .

CYP1A2 INDUCERS & CIGARETTE SMOKING:

                         Both are decreasing the exposure of Erlotinib, while concomitant with Erlocip .

GASTRIC REGULATORS:

                          While concomitant with gastric regulators like proton pump inhibitors, H2 receptors antagonist or antacids, causes depletion of Erlotinib exposure leads to loss of therapeutic effect of Erlotinib. 

ANTICOAGULANTS:

                          In combination of Erlocip 150mg with warfarin, causes increasing international normalized ratio & bleeding adverse reactions. To avoid this problem, monitor the prothrombin time frequently.

EMAIL :millionhealthpharmaceuticals@gmail.com

PHONE NO : +91-9940472902

WEBSITE:

https://millionpharma.com/erlocip.php